Comparing blood tests for measuring biologic drug levels
Treatments studied
Part of Digestive system clinical trials.
This study compares different blood tests that measure the amount of biologic medication in your body. The goal is to see if simpler tests give the same results as standard ones, which could make monitoring easier for patients with inflammatory bowel disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- You must not have had biologic treatments before, or your doctor decides you need a specific biologic now.
- You must be planning to start one of these biologics: infliximab, adalimumab, vedolizumab, or ustekinumab.
- You must not be currently taking antibiotics or have used probiotics/antibiotics in the last month.
- You cannot be pregnant or breastfeeding, and must not have other active autoimmune diseases or tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
This study looks at whether certain blood tests (called inflammatory biomarkers) can help measure how active your inflammatory bowel disease (Crohn's disease or ulcerative colitis) is. It may help doctors better track your condition and guide treatment, without needing invasive procedures.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study tests whether measuring drug levels in the blood can help doctors find the best dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for people with ulcerative colitis or Crohn's disease. It aims to improve control of these conditions while keeping treatment safe.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.